AGN seeks to divest LapBand: http://finance.yahoo.com/news/allergan-reports-third-quarter-2012-130000266.html Allergan is exploring strategic options for maximizing the value of its obesity intervention business, including among other things, a potential sale of that business unit.LapBand is currently selling at an annualized rate of about $160M, about 3% of AGN’s overall sales.